Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab or FOLFOX Plus Cetuximab as First-line Therapy in Subjects With KRAS Wild-type Metastatic Colorectal Cancer (APEC-Study)

NCT00778830 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

289

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: Cetuximab
DRUG: FOLFIRI
DRUG: FOLFOX

Sponsor

Merck KGaA, Darmstadt, Germany

Collaborators

[object Object]